Managing Iron Chelation Therapy in Thalassaemia Patients
Author Information
Author(s): Ceci Adriana, Mangiarini Laura, Felisi Mariagrazia, Bartoloni Franco, Ciancio Angela, Capra Marcello, D'Ascola Domenico, Cianciulli Paolo, Filosa Aldo
Primary Institution: Consorzio per Valutazioni Biologiche e Farmacologiche
Hypothesis
What is the current status of iron chelation therapy in thalassaemic patients in Italy?
Conclusion
The study shows that while oral chelators are preferred for younger patients, many still receive off-label treatments.
Supporting Evidence
- Thalassaemia major requires lifelong blood transfusions, leading to iron overload.
- Deferoxamine has been the standard treatment for many years but has compliance issues.
- New oral chelators like deferiprone and deferasirox have improved patient compliance and quality of life.
Takeaway
This study looks at how thalassaemia patients in Italy are treated for iron overload, showing that younger kids often get different medicines than older patients.
Methodology
This is a multicenter, cross-sectional study analyzing data from a registry of thalassaemic patients.
Potential Biases
Variability in prescription practices among different clinical centers may introduce bias.
Limitations
The study is based on preliminary data and lacks prospective controlled comparative trials.
Participant Demographics
The study included 981 patients, with a balanced gender distribution (47.2% males, 52.8% females) and a mean age of 30.56 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website